APO Research
Talk to an analyst

APO RESEARCH · REPORT

HIV and AIDS Diagnostics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global HIV and AIDS Diagnostics Market Outlook and Growth Opportunities 2026

4 March 2026199 pages

Choose your research edition.

Industry ResearchHIV and AIDS Diagnostics Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV and AIDS Diagnostics Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal HIV and AIDS Diagnostics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV and AIDS Diagnostics Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV and AIDS Diagnostics Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global HIV and AIDS Diagnostics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for HIV and AIDS Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for HIV and AIDS Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HIV and AIDS Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the HIV and AIDS Diagnostics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the HIV and AIDS Diagnostics market include Siemens Healthineers, Bio-Rad, Abbott Laboratories, OraSure TechnologieS, F. Hoffmann-La Roche, Hologic, Abbott, Chembio Diagnostic Systems and BD, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global HIV and AIDS Diagnostics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of HIV and AIDS Diagnostics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents HIV and AIDS Diagnostics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global HIV and AIDS Diagnostics market.

HIV and AIDS Diagnostics Segment by Company

Siemens Healthineers

Bio-Rad

Abbott Laboratories

OraSure TechnologieS

F. Hoffmann-La Roche

Hologic

Abbott

Chembio Diagnostic Systems

BD

Danaher Corporation

HIV and AIDS Diagnostics Segment by Type

Reagent Test Kit

Instrument

Others

HIV and AIDS Diagnostics Segment by Application

Hospitals

Private Diagnostic Laboratories

Academic and Research Institutes

HIV and AIDS Diagnostics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global HIV and AIDS Diagnostics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the HIV and AIDS Diagnostics key companies, revenue, market share, and recent developments.

3. To split the HIV and AIDS Diagnostics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions HIV and AIDS Diagnostics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify HIV and AIDS Diagnostics significant trends, drivers, influence factors in global and regions.

6. To analyze HIV and AIDS Diagnostics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV and AIDS Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV and AIDS Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV and AIDS Diagnostics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global HIV and AIDS Diagnostics industry.

Chapter 3: Detailed analysis of HIV and AIDS Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of HIV and AIDS Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of HIV and AIDS Diagnostics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. HIV and AIDS Diagnostics Industry Trends Table 2. HIV and AIDS Diagnostics Industry Drivers Table 3. HIV and AIDS Diagnostics Industry Opportunities and Challenges Table 4. HIV and AIDS Diagnostics Industry Restraints Table 5. Global HIV and AIDS Diagnostics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global HIV and AIDS Diagnostics Revenue Share by Company (2021-2026) Table 7. Global HIV and AIDS Diagnostics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global HIV and AIDS Diagnostics Key Company Manufacturing Base & Headquarters Table 9. Global HIV and AIDS Diagnostics Company, Product Type & Application Table 10. Global HIV and AIDS Diagnostics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global HIV and AIDS Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Reagent Test Kit Table 15. Significant Companies of Instrument Table 16. Significant Companies of Others Table 17. Global HIV and AIDS Diagnostics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global HIV and AIDS Diagnostics Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global HIV and AIDS Diagnostics Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global HIV and AIDS Diagnostics Sales Value Share by Type (2021-2026) Table 21. Global HIV and AIDS Diagnostics Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospitals Table 23. Significant Companies of Private Diagnostic Laboratories Table 24. Significant Companies of Academic and Research Institutes Table 25. Global HIV and AIDS Diagnostics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global HIV and AIDS Diagnostics Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global HIV and AIDS Diagnostics Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global HIV and AIDS Diagnostics Sales Value Share by Application (2021-2026) Table 29. Global HIV and AIDS Diagnostics Sales Value Share by Application (2027-2032) Table 30. Global HIV and AIDS Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global HIV and AIDS Diagnostics Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global HIV and AIDS Diagnostics Sales Value Share by Region (2021-2026) Table 33. Global HIV and AIDS Diagnostics Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global HIV and AIDS Diagnostics Sales Value Share by Region (2027-2032) Table 35. Global HIV and AIDS Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global HIV and AIDS Diagnostics Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global HIV and AIDS Diagnostics Sales Value Market Share by Country (2021-2026) Table 38. Global HIV and AIDS Diagnostics Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global HIV and AIDS Diagnostics Sales Value Market Share by Country (2027-2032) Table 40. Siemens Healthineers Company Information Table 41. Siemens Healthineers Business Overview Table 42. Siemens Healthineers HIV and AIDS Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Siemens Healthineers HIV and AIDS Diagnostics Product Portfolio Table 44. Siemens Healthineers Recent Development Table 45. Bio-Rad Company Information Table 46. Bio-Rad Business Overview Table 47. Bio-Rad HIV and AIDS Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Bio-Rad HIV and AIDS Diagnostics Product Portfolio Table 49. Bio-Rad Recent Development Table 50. Abbott Laboratories Company Information Table 51. Abbott Laboratories Business Overview Table 52. Abbott Laboratories HIV and AIDS Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Abbott Laboratories HIV and AIDS Diagnostics Product Portfolio Table 54. Abbott Laboratories Recent Development Table 55. OraSure TechnologieS Company Information Table 56. OraSure TechnologieS Business Overview Table 57. OraSure TechnologieS HIV and AIDS Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. OraSure TechnologieS HIV and AIDS Diagnostics Product Portfolio Table 59. OraSure TechnologieS Recent Development Table 60. F. Hoffmann-La Roche Company Information Table 61. F. Hoffmann-La Roche Business Overview Table 62. F. Hoffmann-La Roche HIV and AIDS Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. F. Hoffmann-La Roche HIV and AIDS Diagnostics Product Portfolio Table 64. F. Hoffmann-La Roche Recent Development Table 65. Hologic Company Information Table 66. Hologic Business Overview Table 67. Hologic HIV and AIDS Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Hologic HIV and AIDS Diagnostics Product Portfolio Table 69. Hologic Recent Development Table 70. Abbott Company Information Table 71. Abbott Business Overview Table 72. Abbott HIV and AIDS Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Abbott HIV and AIDS Diagnostics Product Portfolio Table 74. Abbott Recent Development Table 75. Chembio Diagnostic Systems Company Information Table 76. Chembio Diagnostic Systems Business Overview Table 77. Chembio Diagnostic Systems HIV and AIDS Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Chembio Diagnostic Systems HIV and AIDS Diagnostics Product Portfolio Table 79. Chembio Diagnostic Systems Recent Development Table 80. BD Company Information Table 81. BD Business Overview Table 82. BD HIV and AIDS Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. BD HIV and AIDS Diagnostics Product Portfolio Table 84. BD Recent Development Table 85. Danaher Corporation Company Information Table 86. Danaher Corporation Business Overview Table 87. Danaher Corporation HIV and AIDS Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Danaher Corporation HIV and AIDS Diagnostics Product Portfolio Table 89. Danaher Corporation Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. HIV and AIDS Diagnostics Product Image Figure 2. Global HIV and AIDS Diagnostics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV and AIDS Diagnostics Market Size (2021-2032) & (US$ Million) Figure 4. Global HIV and AIDS Diagnostics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Reagent Test Kit Image Figure 8. Instrument Image Figure 9. Others Image Figure 10. Global HIV and AIDS Diagnostics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global HIV and AIDS Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global HIV and AIDS Diagnostics Sales Value Share by Type (2021-2032) Figure 13. Hospitals Image Figure 14. Private Diagnostic Laboratories Image Figure 15. Academic and Research Institutes Image Figure 16. Global HIV and AIDS Diagnostics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global HIV and AIDS Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global HIV and AIDS Diagnostics Sales Value Share by Application (2021-2032) Figure 19. Global HIV and AIDS Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global HIV and AIDS Diagnostics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America HIV and AIDS Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 22. North America HIV and AIDS Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe HIV and AIDS Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 24. Europe HIV and AIDS Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific HIV and AIDS Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific HIV and AIDS Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America HIV and AIDS Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 28. South America HIV and AIDS Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa HIV and AIDS Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa HIV and AIDS Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Reagent Test Kit
  • Instrument
  • Others
Applications
  • Hospitals
  • Private Diagnostic Laboratories
  • Academic and Research Institutes
Companies covered
  • Siemens Healthineers
  • Bio-Rad
  • Abbott Laboratories
  • OraSure TechnologieS
  • F. Hoffmann-La Roche
  • Hologic
  • Abbott
  • Chembio Diagnostic Systems
  • BD
  • Danaher Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global HIV and AIDS Diagnostics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global HIV and AIDS Diagnostics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 HIV and AIDS Diagnostics Market Dynamics
  1. 2.1 HIV and AIDS Diagnostics Industry Trends
  2. 2.2 HIV and AIDS Diagnostics Industry Drivers
  3. 2.3 HIV and AIDS Diagnostics Industry Opportunities and Challenges
  4. 2.4 HIV and AIDS Diagnostics Industry Restraints
3 HIV and AIDS Diagnostics Market by Company
  1. 3.1 Global HIV and AIDS Diagnostics Company Revenue Ranking in 2025
  2. 3.2 Global HIV and AIDS Diagnostics Revenue by Company (2021-2026)
  3. 3.3 Global HIV and AIDS Diagnostics Company Ranking (2024-2026)
  4. 3.4 Global HIV and AIDS Diagnostics Company Manufacturing Base and Headquarters
  5. 3.5 Global HIV and AIDS Diagnostics Company Product Type and Application
  6. 3.6 Global HIV and AIDS Diagnostics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global HIV and AIDS Diagnostics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 HIV and AIDS Diagnostics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 HIV and AIDS Diagnostics Market by Type
  1. 4.1 HIV and AIDS Diagnostics Type Introduction
  2. 4.1.1 Reagent Test Kit
  3. 4.1.2 Instrument
  4. 4.1.3 Others
  5. 4.2 Global HIV and AIDS Diagnostics Sales Value by Type
  6. 4.2.1 Global HIV and AIDS Diagnostics Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global HIV and AIDS Diagnostics Sales Value by Type (2021-2032)
  8. 4.2.3 Global HIV and AIDS Diagnostics Sales Value Share by Type (2021-2032)
5 HIV and AIDS Diagnostics Market by Application
  1. 5.1 HIV and AIDS Diagnostics Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Private Diagnostic Laboratories
  4. 5.1.3 Academic and Research Institutes
  5. 5.2 Global HIV and AIDS Diagnostics Sales Value by Application
  6. 5.2.1 Global HIV and AIDS Diagnostics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global HIV and AIDS Diagnostics Sales Value by Application (2021-2032)
  8. 5.2.3 Global HIV and AIDS Diagnostics Sales Value Share by Application (2021-2032)
6 HIV and AIDS Diagnostics Regional Value Analysis
  1. 6.1 Global HIV and AIDS Diagnostics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global HIV and AIDS Diagnostics Sales Value by Region (2021-2032)
  3. 6.2.1 Global HIV and AIDS Diagnostics Sales Value by Region: 2021-2026
  4. 6.2.2 Global HIV and AIDS Diagnostics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America HIV and AIDS Diagnostics Sales Value (2021-2032)
  7. 6.3.2 North America HIV and AIDS Diagnostics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe HIV and AIDS Diagnostics Sales Value (2021-2032)
  10. 6.4.2 Europe HIV and AIDS Diagnostics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific HIV and AIDS Diagnostics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific HIV and AIDS Diagnostics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America HIV and AIDS Diagnostics Sales Value (2021-2032)
  16. 6.6.2 South America HIV and AIDS Diagnostics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa HIV and AIDS Diagnostics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa HIV and AIDS Diagnostics Sales Value Share by Country, 2025 VS 2032
7 HIV and AIDS Diagnostics Country-level Value Analysis
  1. 7.1 Global HIV and AIDS Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global HIV and AIDS Diagnostics Sales Value by Country (2021-2032)
  3. 7.2.1 Global HIV and AIDS Diagnostics Sales Value by Country (2021-2026)
  4. 7.2.2 Global HIV and AIDS Diagnostics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt HIV and AIDS Diagnostics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt HIV and AIDS Diagnostics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt HIV and AIDS Diagnostics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Siemens Healthineers
  2. 8.1.1 Siemens Healthineers Company Information
  3. 8.1.2 Siemens Healthineers Business Overview
  4. 8.1.3 Siemens Healthineers HIV and AIDS Diagnostics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Siemens Healthineers HIV and AIDS Diagnostics Product Portfolio
  6. 8.1.5 Siemens Healthineers Recent Developments
  7. 8.2 Bio-Rad
  8. 8.2.1 Bio-Rad Company Information
  9. 8.2.2 Bio-Rad Business Overview
  10. 8.2.3 Bio-Rad HIV and AIDS Diagnostics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bio-Rad HIV and AIDS Diagnostics Product Portfolio
  12. 8.2.5 Bio-Rad Recent Developments
  13. 8.3 Abbott Laboratories
  14. 8.3.1 Abbott Laboratories Company Information
  15. 8.3.2 Abbott Laboratories Business Overview
  16. 8.3.3 Abbott Laboratories HIV and AIDS Diagnostics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Abbott Laboratories HIV and AIDS Diagnostics Product Portfolio
  18. 8.3.5 Abbott Laboratories Recent Developments
  19. 8.4 OraSure TechnologieS
  20. 8.4.1 OraSure TechnologieS Company Information
  21. 8.4.2 OraSure TechnologieS Business Overview
  22. 8.4.3 OraSure TechnologieS HIV and AIDS Diagnostics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 OraSure TechnologieS HIV and AIDS Diagnostics Product Portfolio
  24. 8.4.5 OraSure TechnologieS Recent Developments
  25. 8.5 F. Hoffmann-La Roche
  26. 8.5.1 F. Hoffmann-La Roche Company Information
  27. 8.5.2 F. Hoffmann-La Roche Business Overview
  28. 8.5.3 F. Hoffmann-La Roche HIV and AIDS Diagnostics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 F. Hoffmann-La Roche HIV and AIDS Diagnostics Product Portfolio
  30. 8.5.5 F. Hoffmann-La Roche Recent Developments
  31. 8.6 Hologic
  32. 8.6.1 Hologic Company Information
  33. 8.6.2 Hologic Business Overview
  34. 8.6.3 Hologic HIV and AIDS Diagnostics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hologic HIV and AIDS Diagnostics Product Portfolio
  36. 8.6.5 Hologic Recent Developments
  37. 8.7 Abbott
  38. 8.7.1 Abbott Company Information
  39. 8.7.2 Abbott Business Overview
  40. 8.7.3 Abbott HIV and AIDS Diagnostics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Abbott HIV and AIDS Diagnostics Product Portfolio
  42. 8.7.5 Abbott Recent Developments
  43. 8.8 Chembio Diagnostic Systems
  44. 8.8.1 Chembio Diagnostic Systems Company Information
  45. 8.8.2 Chembio Diagnostic Systems Business Overview
  46. 8.8.3 Chembio Diagnostic Systems HIV and AIDS Diagnostics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Chembio Diagnostic Systems HIV and AIDS Diagnostics Product Portfolio
  48. 8.8.5 Chembio Diagnostic Systems Recent Developments
  49. 8.9 BD
  50. 8.9.1 BD Company Information
  51. 8.9.2 BD Business Overview
  52. 8.9.3 BD HIV and AIDS Diagnostics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BD HIV and AIDS Diagnostics Product Portfolio
  54. 8.9.5 BD Recent Developments
  55. 8.10 Danaher Corporation
  56. 8.10.1 Danaher Corporation Company Information
  57. 8.10.2 Danaher Corporation Business Overview
  58. 8.10.3 Danaher Corporation HIV and AIDS Diagnostics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Danaher Corporation HIV and AIDS Diagnostics Product Portfolio
  60. 8.10.5 Danaher Corporation Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst